Pancreas is a disease in pancreas caused by the ingestion of the insulin enzyme, which can be classified as acute and chronic, acute pancreas, which can be divided into two types, one edema and the other haemorrhagic stale. In the treatment of pancreas, the use of antibacterial drugs is an important component, especially in cases where acute pancreas is accompanied by infectious complications.
I. Acute pancreas and antibacterial applications
The early stages of acute pancreas are mostly pure pancreas, at which time it is a chemical inflammation of the incubation of the pancreas itself, without bacterial infection, and therefore does not routinely recommend the preventive use of antibacterial drugs. The premature or inappropriate use of antibacterial drugs can lead to adverse effects such as intestinal herbology disorders and drug resistance. However, in specific types such as cholesterol, early use of antibacterial drugs can be considered due to co-infections such as choreography and choreography.
The use of anti-bacterial drugs is particularly critical when acute pancreas develop into acute insulinitis, where the pancreas tissue is deformed and prone to subsequent infections. The aim is to prevent and control infections in pancreas and insulin-week tissues and to reduce the incidence of mortality and complications.
Principles for the selection of antibacterial drugs
Multiple factors need to be integrated in the selection of antibacterial drugs. The first consideration is antibacterial spectroscopy, which should cover possible pathogens, such as coli, creber, intestinal fungi and intestinal intestinal prostheses such as anaerobic bacteria. Second, drugs need to be able to penetrate the blood pancreas barrier and achieve effective therapeutic concentrations in pancreas tissue. For example, carbon pyroacne-like drugs (e.g. amphibian stalbutano) have a strong antibacterial activity for gland positives, gland cactus and anaerobics, and better penetration of the haemorrhagic insulin barrier is one of the most common drugs for acute insulin infection.
Fluonone-type drugs (e.g., cyclopropasar) may also be used in a number of cases of mild and moderate infections, and fluorine-types are more active for gland cacteria, and hydrazole or nitrazine can be effective for anaerobic bacteria.
III. Medical treatment
The course of treatment for antibacterial drugs is based on the patient ‘ s specific condition. For preventive medications, a possible risk of infection is usually eliminated, e.g., cholesterol pancreas is eliminated for 2 – 3 days. For the treatment of infective pancreas deaths, the treatment process is often long and often takes weeks or months, and when the symptoms of the infection disappear, the body temperature is normal, the count and classification of the external hemorrhage is normal, the CT or ultrasound indicates that the pancreas and the pancreas week are free of infection, a stoppage may be considered, but changes in the condition need to be closely observed to prevent a relapse.
Attention to the application of antibacterial drugs
During the use of antibacterial drugs, adverse reactions of patients, such as allergies, loss of bone marrow function in the liver and kidney, etc., need to be closely monitored. At the same time, care should be taken to prevent the occurrence of double-infection infections, especially in the case of the long-term use of broad-spectral antibacterial drugs, as well as the appearance of diarrhoeal diseases, oral palsy infection, etc. In addition, as antibacterial drugs are being used, the resistance of bacteria is becoming more and more acute, so that the use of drugs should be reasonably regulated in clinical practice, the abuse of antibacterial drugs should be avoided, the programme of drug use should be adapted in a timely manner to the results of the sensitive tests in order to improve treatment and reduce the production of antibacterial bacteria, and to promote good preparation for pancreas patients.
